Qianhong Pharmaceutical announced that in the first three quarters of 2026, it achieved operating income of 1.154 billion yuan, a year-on-year decrease of 5.01%; net profit attributable to shareholders of listed companies was 215 million yuan, a year-on-year decrease of 43.86%; after deducting non-net profit of 200 million yuan, a year-on-year decrease of 26.13%. The third quarter of 2026 achieved revenue of 396 million yuan in a single quarter, up 12.03% year on year; net profit to mother was 62.3322 million yuan, down 50.20% year on year. The decline in performance was mainly affected by demand in overseas markets. The heparin API business declined year-on-year, and the withdrawal of some overdue payments from Jianyuan Trust in the same period last year formed a high base.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.